运动神经元疾病中的反意义寡核酸 (ASOs):在光和阴中治愈的道路
Silvia Cantara1, Giorgia Simoncelli2, Claudia Ricci1
1Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy.
International journal of molecular sciences
|May 11, 2024
概括
反感性寡核酸 (ASOs) 在运动神经元疾病 (MNDs) 中表现有前途. 虽然在脊柱肌缩 (SMA) 和一些ALS病例中是成功的,但ASO治疗的疗效因遗传突变而异.
科学领域:
- 分子生物学分子生物学
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
背景情况:
- 反感性寡核酸 (ASO) 是针对特定mRNA序列的短小寡氧核酸.
- 通过调节基因表达,影响蛋白质水平,ASO提供治疗潜力.
- 像SMA,ALS和SBMA这样的运动神经元疾病 (MND) 是ASO发展的目标.
研究的目的:
- 审查当前对运动神经元疾病 (MNDs) 的反感性寡核酸 (ASO) 研究.
- 在临床试验中分析ASO疗法的成功,失败,优势和局限性.
- 建议未来的方向,以更有效的ASO治疗MNDs.
主要方法:
- 对MND的ASO进行临床前研究和临床试验的审查.
- 对ASO疗法的监管批准进行分析.
- 基于特定的遗传突变 (例如,在ALS中SOD1,C9orf72) 的ASO疗效的评估.
主要成果:
- 努辛森 (Nusinersen) 是一种被批准的,有效的脊柱肌缩 (SMA) 疗法.
- 托弗森是一种ASO,已被批准用于患有SOD1基因突变的ALS患者.
- 在患有C9orf72突变的ALS患者中,ASO治疗没有改善疾病进展.
结论:
- ASO疗法在治疗特定的MND如SMA和某些ALS亚型方面取得了显著的成功.
- ASO的有效性高度依赖于向的基因突变和疾病背景.
- 需要进一步的研究来优化ASO设计和交付,以获得更广泛,更有效的MND治疗.
相关概念视频
02:30siRNA - Small Interfering RNAs
16.7K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.7K
01:15Parkinson's Disease: Overview
533
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
533
02:15Experimental RNAi
6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
674
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
674
01:24Parkinson's Disease: Treatment
263
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
263